CXCR3 Antagonist NBI-74330 Attenuates Atherosclerotic Plaque Formation in LDL Receptor–Deficient Mice
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Objective— The chemokine receptor CXCR3 is implicated in migration of leukocytes to sites of inflammation. Antagonizing CXCR3 may be a strategy to inhibit inflammation-induced leukocyte migration and subsequently reduce atherosclerosis. We used the CXCR3 specific antagonist NBI-74330 to block CXCR3-mediated signaling in peritonitis and diet-induced atherosclerosis. Methods and Results— Antagonizing CXCR3 with NBI-74330 resulted in a significant reduction in CD4 + T cell and macrophage migration to the peritoneal cavity, which was as shown in ex vivo migration studies totally CXCR3 dependent. Atherosclerotic lesion formation in the aortic valve leaflet area and the entire aorta was significantly inhibited in NBI-74330 treated mice. Lymph nodes draining from the aortic arch were significantly smaller in treated mice and were enriched in regulatory T cells and contained fewer activated T cells, whereas the markers for regulatory T cells within the lesion were enhanced after NBI-74330 treatment. Conclusion— This study shows for the first time that treatment with a CXCR3 antagonist results in attenuating atherosclerotic lesion formation by blocking direct migration of CXCR3 + effector cells from the circulation into the atherosclerotic plaque and by beneficially modulating the inflammatory response in the lesion and the lymph nodes draining from the atherosclerotic lesion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Qin, S., Rottman, J. B., Myers, P., Kassam, N., Weinblatt, M., Loetscher, M., Koch, A. E., Moser, B., & Mackay, C. R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1422 · Cited by 1,359
Dufour, J. H., Dziejman, M., Liu, M. T., Leung, J. H., Lane, T. E., & Luster, A. D. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.7.3195 · Cited by 1,075
Cited by
Atherosclerosis: current pathogenesis and therapeutic options
Weber, C., & Noels, H. (2011) · Nature Medicine · doi:10.1038/nm.2538 · Cited by 2,203
Obesity, inflammation, and atherosclerosis
Rocha, V. Z., & Libby, P. (2009) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.55 · Cited by 994
Inflammation in Atherosclerosis: Transition From Theory to Practice
Libby, P., Okamoto, Y., Rocha, V. Z., & Folco, E. (2010) · Circulation Journal · doi:10.1253/circj.cj-09-0706 · Cited by 799
T cell subsets and functions in atherosclerosis
Saigusa, R., Winkels, H., & Ley, K. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0352-5 · Cited by 721
Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets
Ramji, D. P., & Davies, T. S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.04.003 · Cited by 469
Metadata
- Authors
- van Wanrooij, E. J. A., de Jager, S. C. A., van Es, T., de Vos, P., Birch, H. L., Owen, D. A., Watson, R. J., Biessen, E. A. L., Chapman, G. A., van Berkel, T. J. C., & Kuiper, J.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2008-02
- Volume
- 28
- Issue
- 2
- Pages
- 251-257
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W1997284331
- Cited by
- 121
- References
- 3
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CXCR3 Antagonist NBI-74330 Attenuates Atherosclerotic Plaque Formation in LDL Receptor–Deficient Mice. https://app.cochat.ai/papers/10.1161/atvbaha.107.147827
- The paper
- van Wanrooij, E. J. A., de Jager, S. C. A., van Es, T., de Vos, P., Birch, H. L., Owen, D. A., Watson, R. J., Biessen, E. A. L., Chapman, G. A., van Berkel, T. J. C., & Kuiper, J. (2008). CXCR3 Antagonist NBI-74330 Attenuates Atherosclerotic Plaque Formation in LDL Receptor–Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.107.147827
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.